

**FoI request re: advanced breast cancer**  
**Ref: 19-JS-0310**

Dear,

Thank you for your request for information relating to advanced breast cancer.

This was received on 5 September 2019 and has been dealt with under the terms of the Freedom of Information Act 2000.

Please find our responses below:

**Request 1:**

Does your trust treat advanced breast cancer? [Yes](#)

**Request 2:**

If none, where are your patients referred? [N/A](#)

**Request 3:**

In the past 3 months, how many advanced breast cancer patients [Stage IV] have the status of?

HR+ and HER2+ [Hormone receptor-positive and human epidermal growth factor 2-positive]	
HR+ and HER2- [Hormone receptor-positive and human epidermal growth factor 2-negative]	
HR- and HER2+ [Hormone receptor-negative and human epidermal growth factor 2-positive]	
HR- and HER2- [Hormone receptor-negative and human epidermal growth factor 2-negative] - Triple negative disease	
Not Known	

We can neither confirm nor deny whether the information you have requested is held by the Trust in its entirety. This is because the information requested is not held in an easily retrievable format and would require for a clinician to manually identify and go through individual patient records.

We therefore estimate that complying with your request is exempt under section 12 of the FOI Act: *cost of compliance is excessive*. The section 12 exemption applies when it is estimated a request will take in excess of 18 hours to complete. We estimate that accessing and reviewing all health records and then extracting relevant information would take longer than the 18 hours allowed for.

Whittington Health NHS Trust

Interim Chair: David Holt    Chief Executive: Siobhan Harrington

**Request 4:**

In the past 3 months, how many breast cancer patients were treated with?

<b>Abemaciclib (Verzenios) + aromatase inhibitor *</b>	0
<b>Abemaciclib (Verzenios) + Fulvestrant (Faslodex)</b>	≤5
<b>Alpelisib (Piqray) + Fulvestrant (Faslodex)</b>	0
<b>Atezolizumab (Tecentriq)**</b>	0
<b>Bevacizumab (Avastin)</b>	0
<b>Eribulin (Halaven)</b>	0
<b>Everolimus (Afinitor) + Exemestane</b>	0
<b>Fulvestrant (Faslodex) as a single agent</b>	9
<b>Gemcitabine + paclitaxel</b>	0
<b>Lapatinib (Tyverb)</b>	0
<b>Neratinib (Nerlynx)</b>	0
<b>Olaparib (Lynparza)</b>	0
<b>Palbociclib (Ibrance) + aromatase inhibitor*</b>	≤5
<b>Pertuzumab (Perjeta) + trastuzumab + docetaxel</b>	≤5
<b>Ribociclib (Kisqali) + aromatase inhibitor*</b>	0
<b>Ribociclib (Kisqali) + Fulvestrant (Faslodex)</b>	0
<b>Talazoparib (Talzenna)</b>	0
<b>Trastuzumab + paclitaxel</b>	≤5
<b>Trastuzumab as a single agent</b>	16
<b>Trastuzumab emtansine (Kadcyla)</b>	≤5
<b>Other active systemic anti-cancer therapy **</b>	

\*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole

\*\*eg. docetaxel, vinorelbine or capecitabine as a single agent

We are not able to provide you with the information in regards to other active systemic anti-cancer therapy because the information requested is not held in an easily retrievable format and would require to go through a large number of documents

We therefore estimate that complying with your request is exempt under section 12 of the FOI Act: *cost of compliance is excessive*. The section 12 exemption applies when it is estimated a request will take in excess of 18 hours to complete. We estimate that accessing and reviewing all documents and then extracting relevant information would take longer than the 18 hours allowed for.

Please note that the trust's policy is not to provide patient or staff numbers, where the response is less than or equal to five (≤5) as it would potentially allow identification of the individual patient/staff and would therefore be personal data. The trust considers that release of that information would breach GDPR/DPA18 principles on the grounds that it would not be fair in all the circumstances. This information is therefore exempt under section 40 of the FOI Act 2000.

I hope you find this information useful. Please quote the above reference in any further communication on this matter.

Whittington Health NHS Trust

Interim Chair: David Holt    Chief Executive: Siobhan Harrington

If you require any further assistance, please do not hesitate to contact me by email or at the address shown below.

Yours sincerely

FOI Coordinator  
**Freedom of Information Office**  
Whittington Health  
Highgate Wing, Level 5  
Magdala Avenue  
London, N19 5NF  
[foi.whitthealth@nhs.net](mailto:foi.whitthealth@nhs.net)



---

If you are dissatisfied with this response, Whittington Health operates a complaints procedure, details of which can be found below:

**FOI Complaints:**

In the first instance, write to:

**Director Lead for Information Governance**

Chief Operating Officer  
Jenner Building  
Magdala Avenue  
London  
N19 5NF  
020 7288 5255  
[foi.whitthealth@nhs.net](mailto:foi.whitthealth@nhs.net)

If you remain dissatisfied with the Trust's response, you may write to:

**Information Commissioner's Office**

Wycliffe House  
Water Lane  
Wilmslow  
Cheshire SK9 5AF  
Telephone: 0303 123 1113 or 01625 545745  
[www.ico.org.uk](http://www.ico.org.uk)

---

Whittington Health NHS Trust

Interim Chair: David Holt    Chief Executive: Siobhan Harrington